Dr. Salgia on Importance of Molecular Markers in Lung Cancer

In Partnership With:

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Lung cancer can be subdivided into histology subtypes, like non-small cell lung cancer (NSCLC) and small cell lung cancer. There are also adenocarcinomas, nonsquamous cell carcinomas, squamous cell carcinomas, and sometimes large cell carcinomas, but there are also subsets in terms of molecular markers, Salgia adds. There are EGFR mutations, ALK translocations, or ROS1 translocations, which can be discovered through a molecular test.

Salgia says that molecular testing is imperative and standard. Molecular testing can indicate a targetable pathway for a patient, and can open up additional treatment options if the patient harbors a particular mutation. As a standard practice in NSCLC, molecular testing has transformed therapeutic approaches and sequencing for patients.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content